In a patient with Crohn’s disease on sulfasalazine and mesalamine who presents with left‑sided chest pain, what is the appropriate evaluation and management?

Immediate Evaluation for Drug-Induced Myopericarditis

In a Crohn's patient on sulfasalazine and mesalamine presenting with left-sided chest pain, immediately discontinue both 5-ASA agents and evaluate for drug-induced myopericarditis—a rare but potentially life-threatening hypersensitivity reaction that typically occurs within 2-4 weeks of drug initiation.

Critical First Steps

Stop all 5-ASA medications immediately while awaiting cardiac evaluation. Both mesalamine and sulfasalazine can cause myocarditis, pericarditis, or pleuropericarditis through hypersensitivity mechanisms 1, 2. This is a medical emergency that requires prompt recognition.

Specific Diagnostic Workup

Obtain the following immediately:

• ECG: Look for ST-segment elevation (particularly in leads I, aVL, or diffuse with upward concavity suggesting pericarditis) 3, 4, 5
• Cardiac biomarkers: Troponin I elevation (can be significantly elevated, e.g., >1.8 ng/mL) 4, 5
• Inflammatory markers: ESR and CRP (often markedly elevated, e.g., ESR >100 mm, CRP >180 mg/L) 4
• Echocardiogram: Assess for pericardial effusion, left ventricular systolic dysfunction, or global hypocontractility 3, 5
• Chest imaging: CT or X-ray to evaluate for pleural effusion and cardiomegaly 3, 6

Key Clinical Features to Recognize

The presentation typically includes:

• Pleuritic chest pain (often left-sided, may radiate to shoulder or neck) 3, 5, 7
• Fever (common presenting symptom) 3, 8
• Dyspnea (especially when lying down) 6, 7
• Onset 2-4 weeks after starting 5-ASA therapy 5, 7

Critical Pitfall: Steroid Masking

If the patient is on concurrent corticosteroids for Crohn's flare, symptoms may be partially suppressed, leading to delayed diagnosis 6. The inflammatory response can be masked, making clinical manifestations less obvious. Maintain high suspicion even with milder symptoms.

Distinguishing Drug Reaction from Crohn's Extraintestinal Manifestation

This is challenging but critical:

• Drug-induced: Temporal relationship to medication initiation (typically 2-4 weeks), rapid improvement after drug cessation (within days), positive drug lymphocyte stimulation test if available 3, 5, 7
• Crohn's extraintestinal manifestation: Correlation with GI disease activity, history of similar episodes during previous flares, no clear temporal relationship to medication changes 4, 9

The key differentiator is clinical response: Drug-induced myopericarditis improves rapidly (within 2-7 days) after stopping the offending agent 3, 5, 7. If symptoms persist beyond one week off 5-ASA, consider true extraintestinal manifestation.

Management Algorithm

1. Discontinue sulfasalazine and mesalamine immediately 1, 2
2. Cardiology consultation for hemodynamic monitoring and consideration of cardiac MRI (shows subepicardial fibrosis/enhancement in myocarditis) 4, 5
3. If pericardial effusion present: Monitor for tamponade physiology; thoracentesis may be needed for large effusions 3, 6
4. Supportive cardiac therapy: Colchicine for pericarditis component if confirmed 4
5. Increase corticosteroid dose if patient is already on steroids for Crohn's management 4, 9

Alternative Crohn's Management

5-ASA agents have no role in Crohn's disease management 10. Current guidelines strongly recommend against their use for induction or maintenance of remission in Crohn's disease 11, 12, 10.

For mild colonic Crohn's disease, the only conditional recommendation for sulfasalazine exists at 4-6 g/day 12, but given this patient's cardiac presentation, never rechallenge with any 5-ASA compound 1, 2.

Appropriate Alternative Therapies

• Budesonide 9 mg daily for ileal/right colonic disease 12, 10
• Prednisone 40-60 mg daily for moderate disease 12
• Thiopurines (azathioprine 2-2.5 mg/kg/day) for maintenance 13, 14
• Anti-TNF therapy for moderate-severe or refractory disease 14

Atypical Presentations to Consider

• Neutrophil-dominant effusions (rather than typical eosinophilic pattern) can occur, mimicking bacterial infection 6
• Eosinophilic pneumonia with bilateral infiltrates and peripheral eosinophilia 8
• Recurrent episodes can occur with drug rechallenge, potentially with tamponade physiology 6

Prognosis

With prompt discontinuation of 5-ASA agents, clinical symptoms, cardiac biomarkers, and ventricular function typically improve within days to weeks 3, 5, 7. However, cardiac MRI may show persistent subepicardial fibrosis 5. Never restart any 5-ASA compound in this patient 1, 2.